2 Cathie Wood ARK stocks I’d buy today

ARK Invest’s Cathie Wood is one of the biggest names in investing right now. Here are two stocks she owns that Edward Sheldon would buy today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cathie Wood is one of the biggest names in investing right now. It’s not hard to see why. Over the last year, her ARK Innovation ETF has returned 144% for investors.

Here, I’m going to highlight two Wood-owned stocks I’d buy for my own portfolio today. Both have done well over the last year. However, I also believe they’ve a lot of growth ahead.

A top Cathie Wood stock

One Wood stock I like a lot is Teladoc Health (NYSE: TDOC). The leading provider of virtual healthcare services is currently the fourth largest position in the ARK Innovation ETF.

The reason I’m bullish here is I expect the virtual healthcare industry to grow substantially in the years ahead. Ultimately, telemedicine is a win for both patients and healthcare companies. For patients, it’s more convenient. Meanwhile, for healthcare professionals, it’s far more time-effective. According to Mordor Intelligence, the global virtual healthcare market will roughly triple between now and 2026.

TDOC posted a strong set of fourth-quarter and full-year 2020 results last week. For Q4, revenue was up 145% year-on-year to $383m with total visits up 139% to 3m. For the full year, revenue was up 98% year-on-year to $1,094m with total visits up 156% to 10.6m. Adjusted EBITDA for the full year was $126.8m compared to $31.8m for 2019.

There are some risks to be aware of here. One is the valuation. Currently, TDOC has a market-cap of $33bn which equates to a forward-looking price-to-sales ratio of about 17. That’s a high valuation. If future results are disappointing, the shares could fall. The company is also facing competition from the likes of CVS Health.

Overall, however, I think the long-term story here is very attractive. I see the recent share price weakness as a buying opportunity.

An e-commerce powerhouse

Another Wood stock I’m excited about is e-commerce platform Shopify (NYSE: SHOP). The business makes it easy for merchants to build digital storefronts and manage their online operations. Shopify is currently a top 10 holding in both the ARK Innovation ETF and the ARK Fintech Innovation ETF.

The reason I like SHOP is that I expect the e-commerce industry to get much much bigger in the years ahead. By 2027, the global market is set to be worth around $10trn, up from around $4trn in 2020, driven by escalating mobile usage. This market growth should benefit Shopify.

Recent Q4 and full-year results here were impressive. Revenue for Q4 was up 94% to $978m while full-year revenue was up 86% to $2.3bn. The company did warn, however, that sales growth could moderate in 2021 as some consumer spending moves back to retail stores.

Like TDOC, Shopify is an expensive stock. Currently, it has a market-cap of $157bn and sports a price-to-sales ratio of 38. So, there’s certainly some valuation risk here. Another risk to consider is competition in the e-commerce space. Recently, Amazon acquired Selz, a company that also helps businesses launch their own online stores. This suggests Amazon is planning to compete more directly with SHOP.

Given the high valuation, this isn’t a growth stock I’d load up on. However, after the recent share price pullback, I’d be happy to buy a small position for my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in Amazon, Teladoc Health and Shopify. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool UK owns shares of and has recommended Amazon, Shopify, and Teladoc Health and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£3,000 in savings? Here’s how I’d use that to start earning a monthly passive income

Our writer digs into the details of how spending a few thousand pounds on dividend shares now could help him…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BP share price in the next three years

I can understand why the BP share price is low, as oil's increasingly seen as evil. But BP's a cash…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »